Sofia R Bartlett

Sofia R Bartlett
BC Centre for Disease Control · Clinical Prevention Services

BSc (Hons) PhD

About

68
Publications
3,881
Reads
How we measure 'reads'
A 'read' is counted each time someone views a publication summary (such as the title, abstract, and list of authors), clicks on a figure, or views or downloads the full-text. Learn more
445
Citations
Introduction
My program of research is public health focused, seeking to address knowledge gaps around the overlap of viral hepatitis, HIV, drug use, and incarceration that have the potential to inform public health policy and programming, while advancing the rights and the health of marginalized people. The main focus of my current work is identifying strategies to address inequities in hepatitis C virus treatment uptake, using linked administrative health data-sets and epidemiological techniques.

Publications

Publications (68)
Article
Full-text available
Background and aims: In moving towards the elimination of hepatitis C virus (HCV) infection among people living with HIV, understanding HCV transmission patterns may provide insights to guide and evaluate interventions. In this study, we evaluated patterns of, and factors associated with HCV phylogenetic clustering among people living with HIV/HCV...
Article
Full-text available
Purpose Several non-pharmaceutical interventions, such as physical distancing, handwashing, self-isolation, and school and business closures, were implemented in British Columbia (BC) following the first laboratory-confirmed case of COVID-19 on 26 January 2020, to minimise in-person contacts that could spread infections. The BC COVID-19 Population...
Article
Full-text available
We investigate the diagnostic accuracy and predictive value of finger prick capillary dried blood spot (DBS) samples tested by a quantitative multiplex anti-immuno-globulin G (IgG) assay to detect severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies after infection or vaccination. This cross-sectional study involved participants...
Article
Purpose Several non-pharmaceutical interventions such as physical distancing, self-isolation, a stay-at-home order, hand washing, and schools and businesses closures were implemented in British Columbia (BC) following the first lab-tested case of COVID-19 on January 26, 2020. These interventions were aimed at minimizing in-person contacts that coul...
Article
Full-text available
Importance Initiation of injection drug use may be more frequent among people dispensed prescription opioid therapy for noncancer pain, potentially increasing the risk of hepatitis C virus (HCV) acquisition. Objective To assess the association between medically dispensed long-term prescription opioid therapy for noncancer pain and HCV seroconversi...
Article
Full-text available
The true severity of infection due to COVID-19 is under-represented because it is based on only those who are tested. Although nucleic acid amplifications tests (NAAT) are the gold standard for COVID-19 diagnostic testing, serological assays provide better population-level SARS-CoV-2 prevalence estimates. Implementing large sero-surveys present sev...
Article
https://blog.catie.ca/2021/11/18/how-rwanda-is-eliminating-hepatitis-c-and-what-canada-can-learn-from-its-successes/?fbclid=IwAR1xY-oW2yr9NA7E8KU9Qhi48M6l8Yb0PhKfxY9P3AQMRbGfJyyWxbVSqTw
Article
The use of person-centred language is well accepted regarding substance use and infectious disease healthcare and research, and appropriate acronyms have become commonplace, e.g., "people who inject drugs (PWID)" has mostly replaced phrases like "injecting drugs users". However, the use of the term's 'prisoner' or 'prisoners' remains common. Althou...
Article
Full-text available
Background Women living with hepatitis C virus (HCV) are rarely addressed in research and may be overrepresented within key populations requiring additional support to access HCV care and treatment. We constructed the HCV care cascade among people diagnosed with HCV in British Columbia, Canada, as of 2019 to compare progress in care and treatment a...
Article
Background & Aims Public health measures introduced to limit transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which causes coronavirus disease 2019 (COVID-19), also disrupted various healthcare services in many regions worldwide, including British Columbia (BC), Canada. We assessed the impact of these measures, first in...
Preprint
Full-text available
Introduction Several non-pharmaceutical interventions such as physical distancing, hand washing, self-isolation, and schools and business closures, were implemented in British Columbia (BC) following the first laboratory-confirmed case of coronavirus disease 2019 (COVID-19) on January 26, 2020, to minimize in-person contacts that could spread infec...
Preprint
Full-text available
Importance: Measuring humoral immunogenicity of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines and finding population-level correlates of protection against coronavirus disease (COVID-19) presents an immediate challenge to public health practitioners. Objective: To study the diagnostic accuracy and predictive value of finger...
Article
Background Evidence that opioid agonist therapy (OAT) is associated with increased odds of hepatitis C virus (HCV) treatment initiation among people who use drugs (PWUD) is emerging. The objective of this study was to determine the association between current OAT and HCV treatment initiation among PWUD in a population-level linked administrative da...
Article
Background: We evaluated the effect of sustained virologic response(SVR) from direct acting antiviral(DAA) treatments on all-cause, liver- and drug-related mortality in a population-based cohort in British Columbia(BC), Canada. Methods: We used data from the BC Hepatitis Testers Cohort, which includes people tested for hepatitis C virus(HCV) sin...
Article
Full-text available
Introduction Increasing evidence indicates that chronic hepatitis C virus (HCV) infection is associated with higher risk of diabetes. Previous studies showed ethnic disparities in the disease burden of diabetes, with increased risk in Asian population. We described the incidence of type 2 diabetes related to HCV infection and assessed the concurren...
Preprint
Full-text available
The true severity of infection due to COVID-19 is under-represented because it is based on only those who are tested. Although nucleic acid amplifications tests (NAAT) are the gold standard for COVID-19 diagnostic testing, serological assays provide better population-level SARS-CoV-2 prevalence estimates. Implementing large sero-surveys present sev...
Article
Full-text available
Background: Delivery of hepatitis C virus (HCV) care to people in prison is essential to HCV elimination. We aimed to describe current HCV care practices across Canada's adult provincial prisons. Methods: One representative per provincial prison health care team (except Ontario) was invited to participate in a web-based survey from January to Ju...
Article
Full-text available
Objective Current guidelines in British Columbia recommend prenatal screening for hepatitis C antibodies (anti-HCV) if risk factors are present. We aimed to estimate frequency of prenatal anti-HCV testing, new diagnoses, repeated and follow-up testing among BC women. Methods BC Centre for Disease Control Public Health Laboratory data estimated the...
Article
Background & Aims Hepatitis C virus (HCV) reinfection among high‐risk groups threatens HCV elimination goals. We assessed HCV reinfection rates among men who have sex with men (MSM) in British Columbia (BC), Canada. Methods We used data from the BC Hepatitis Testers Cohort, which includes nearly 1.7 million individuals tested for HCV or HIV in BC....
Article
Background The majority of new HCV infections in Canada occur in people who inject drugs. Thus, while curative direct antiviral agents (DAAs) herald a promising new era in hepatitis C virus (HCV) treatment, improving the lives and wellbeing of people living with HCV (PLHCV) must be considered in the context of reducing overdose-related harms and wi...
Article
Full-text available
People who use drugs (PWUD) face concurrent public health emergencies from overdoses, HIV, hepatitis C, and COVID-19, leading to an unprecedented syndemic. Responses to PWUD that go beyond treatment—such as decriminalization and providing a safe supply of pharmaceutical-grade drugs—could reduce impacts of this syndemic. Solutions already implemente...
Article
Full-text available
Background Hepatitis C (HCV) affects diverse populations such as people who inject drugs(PWID), baby boomers’, gay/bisexual men who have sex with men(gbMSM), and people from HCV endemic regions. Assessing HCV syndemics (i.e.relationships with mental health/chronic diseases), among subpopulations using Latent Class Analysis(LCA) may facilitate targe...
Article
Background. Clinical trials show high efficacy of sofosbuvir/velpatasvir (SOF/VEL), but there are limited data from "real-world" settings. We aimed to evaluate SOF/VEL effectiveness for all hepatitis C virus (HCV) genotypes (GTs) in British Columbia (BC), Canada. Methods. We used the BC Hepatitis Testers Cohort, which includes all HCV cases in the...
Article
Full-text available
Background: Micro-elimination of HCV among people living with HIV may be feasible in Australia, given unrestricted access to direct-acting antiviral (DAA) therapy from 2016. Our aim was to evaluate progress towards elimination goals within HIV/HCV co-infected adults in Australia following universal DAA access. Methods: The CEASE prospective coho...
Article
Effectiveness of direct‐acting antiviral (DAA) therapies could be influenced by patient characteristics such as co‐morbid conditions, which could lead to premature treatment discontinuation and/or irregular medical follow‐ups. Here we evaluate loss to follow‐up and treatment effectiveness of sofosbuvir/ledipasvir ±ribavirin (SOF/LDV±RBV), ombitasvi...
Article
Background & aims: HCV infection is associated with several extrahepatic manifestations (EHMs). We evaluated the impact of sustained virological response (SVR) on the risk of 7 EHMs that contribute to the burden of extrahepatic disease: type 2 diabetes mellitus, chronic kidney disease or end-stage renal disease, stroke, ischemic heart disease, maj...
Article
Background: Population-level monitoring of hepatitis C virus (HCV) infected people across cascades of care identifies gaps in access and engagement in care and treatment. We characterized the population-level care cascade for HCV in British Columbia (BC), Canada before and after introduction of Direct Acting Antiviral (DAA) treatment. Methods: B...
Conference Paper
Full-text available
Background Improvements in tolerability and cure rates of hepatitis C virus (HCV) with direct acting antiviral (DAA) treatment led to expansion of patients treated for HCV; however, research examining the impact of these changes on linkage to care and treatment initiation among patients with hepatitis B (HBV) and HIV co-infection is limited. We com...
Conference Paper
Background HIV, hepatitis B virus (HBV) and hepatitis C virus (HCV) infections each are associated with increased cancer risk. In this study, we assessed the effect of co-occurrence of HIV, HBV and HCV on all cancers, anal cancer, non-Hodgkin Lymphoma (NHL) and liver cancer. Methods We used the British Columbia Hepatitis Testers Cohort (BC-HTC) wh...
Data
Data S1. Supplementary Materials and Methods. Figure S1. Maximum likelihood phylogenetic trees inferred from available hepatitis C virus (HCV) Core‐E2 sequence from five studies of recent HCV infection in Australia and New Zealand recruited between 2004 and 2015. Table S1. Multivariate logistic regression of factors associated with phylogenetic c...
Article
Full-text available
Introduction Over the last two decades, the incidence of hepatitis C virus (HCV) co‐infection among men who have sex with men (MSM) living with HIV began increasing in post‐industrialized countries. Little is known about transmission of acute or recent HCV, in particular among MSM living with HIV co‐infection, which creates uncertainty about potent...
Article
Full-text available
Micro-elimination of hepatitis C virus (HCV) infection through rapid uptake of government-funded direct-acting antiviral (DAA) therapy within an Australian prison setting is demonstrated. During a 22 month period, 119 patients initiated treatment for chronic HCV infection, with HCV in-prison viremic prevalence declining from 12% to 1%.
Article
Full-text available
The significance of the clinical impact of direct-acting antiviral (DAA) resistance-associated substitutions (RASs) in hepatitis C virus (HCV) on treatment failure is unclear. No standardized methods or guidelines for detection of DAA RASs in HCV exist. To facilitate further evaluations of the impact of DAA RASs in HCV, we conducted a systematic re...
Article
Combining phylogenetic and network methodologies has the potential to better inform targeted interventions to prevent and treat infectious diseases. This study reconstructed a molecular transmission network for people with recent hepatitis C virus (HCV) infection and modelled the impact of targeting directly acting antiviral (DAA) treatment for HCV...
Article
The aim of this study was to identify factors associated with phylogenetic clustering among people with recently acquired hepatitis C virus (HCV) infection. Participants with available sample at time of HCV detection were selected from three studies; the Australian Trial in Acute Hepatitis C, the Hepatitis C Incidence and Transmission Study - Priso...
Article
Full-text available
Sequencing is important for understanding the molecular epidemiology and viral evolution of hepatitis C virus (HCV) infection. To date, there is little standardisation among sequencing protocols, in-part due to the high genetic diversity that is observed within HCV. This study aimed to develop a novel, practical sequencing protocol that covered bot...
Article
Full-text available
Many people living with hepatitis C virus (HCV) infection will continue to rely on interferon-based regimens until effective strategies to minimize the cost of directly acting antivirals (DAAs) and to improve treatment access are implemented. Host single-nucleotide polymorphisms related to IFNL3 and IFNL4 are associated with spontaneous clearance o...
Article
Full-text available
In bacteria, phosphoenolpyruvate synthetase (EC 2.7.9.2) catalyses the conversion of pyruvate to phosphoenolpyruvate during gluconeogenesis. The enzyme is regulated by an unusual bifunctional serine/threonine kinase-phosphotransferase (PEP synthetase regulatory protein) that involves an ADP-dependent phosphorylation and a Pi-dependent dephosphoryla...

Network

Cited By

Projects

Projects (4)
Project
Understanding coverage of STBBI testing, patterns in test uptake and impact of changes in testing on notifications/cases
Project
Developing methods to construct and analyses care cascades for STBBIs and there related syndemics.